Increased risk of cardiovascular diseases in patients with chronic hypoparathyroidism in Sweden.

Journal: The Journal Of Clinical Endocrinology And Metabolism
Published:
Abstract

Background: Data on cardiovascular outcomes in patients with chronic hypoparathyroidism (hypoPT) are limited.

Objective: To investigate the risk of cardiovascular outcomes; acute myocardial infarction, atrial fibrillation/flutter, heart failure, valvular heart disease, peripheral artery disease and stroke/transient ischemic attack (TIA) in patients with chronic hypoPT.

Methods: The Swedish National Patient Registry, the Swedish Prescribed Drug Registry, and the Total Population Registry, 1997-2018. Methods: Population-based cohort study in Sweden. Methods: National registries were used to identify patients with chronic hypoPT and matched controls.

Results: A total of 1,982 with chronic hypoPT and 19,499 controls were included. After adjustment for cardiovascular risk factors, patients with chronic hypoPT had higher risk of valvular heart disease (HR 2.08; 95% CI 1.67-2.60), peripheral artery disease (HR 1.78; 95% CI 1.41-2.26), heart failure (HR 1.66; 95% CI 1.44-1.90), atrial fibrillation/flutter (HR 1.58; 95% CI 1.38-1.81), acute myocardial infarction (HR 1.31; 95% CI 1.05-1.64) and fatal cardiovascular disease (HR 1.59; 95% CI 1.40-1.80) compared to matched controls. No significant difference in risk of stroke/TIA was observed. Cardiovascular outcomes did not differ between patients with surgical- and non-surgical chronic hypoPT. Females with hypoPT and a significantly increased risk of valvular heart disease, peripheral artery disease, heart failure, atrial fibrillation, myocardial infarction and fatal CV disease compared to female controls. There were no differences in any cardiovascular outcomes between males with hypoPT and male controls.

Conclusions: The risk of cardiovascular diseases was increased in patients with chronic hypoPT, particularly among women. These findings highlight the need for close monitoring and preventive management of cardiovascular risk factors, especially in women.